Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Ask an Advisor: I'm 47 With $1.87 Million But I'm ‘Burned Out' From My Stressful Career. Can I Retire Early at 51?

View original at finance.yahoo.com
Ask an Advisor: I'm 47 With $1.87 Million But I'm ‘Burned Out' From My Stressful Career. Can I Retire Early at 51? Help me! I read the column frequently-huge fan!I'm 47, married, and severely burned out after 25+ years in a fast-paced and stressful field…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Social Security statement estimates won't be accurate for early retirees because they assume continued earnings at current level

    80% confidence
  • Most people with Scott's assets and income sources would be able to comfortably retire at 51

    80% confidence
  • Severely burned out after 25+ years in a fast-paced and stressful field

    80% confidence
  • Actual Social Security benefit is likely to be meaningfully lower than statement estimates for early retirees

    80% confidence
  • Retirement success is driven by whether assets can reliably support spending, not by portfolio size alone

    80% confidence
  • Scott is probably looking at a very active period for the next 15-20 years based on his age

    80% confidence
  • People tend to spend more in early retirement years when active, with spending slowing with age and picking back up for health expenses

    80% confidence
  • Plans to sell primary residence in around three years and buy something all cash somewhere warm

    80% confidence
  • If spending needs are similar to average person, Scott can almost certainly retire at 51 with his assets

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com